As of September 30, 2026, BeOne Medicines Ltd. carries a market capitalization of 439.40B, placing it among publicly traded companies globally. Its enterprise value stands at 403.06B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 439.40B |
| Enterprise Value | 403.06B |
BeOne Medicines Ltd.'s next confirmed earnings release is scheduled for March 31, 2027.
| Earnings Date | 3/31/2027 |
As of September 30, 2026, BeOne Medicines Ltd. has 1.95B shares outstanding.
| Shares Outstanding | 1.95B |
As of September 30, 2026, BeOne Medicines Ltd. trades at a trailing price-to-earnings ratio of 60.08. The price-to-sales ratio is 8.33, and the price-to-book ratio stands at 9.62.
| PE Ratio | 60.08 |
| PS Ratio | 8.33 |
| PB Ratio | 9.62 |
| P/TBV Ratio | 9.69 |
| P/FCF Ratio | 39.99 |
| P/OCF Ratio | 34.59 |
As of September 30, 2026, BeOne Medicines Ltd. trades at an EV/EBITDA multiple of 37.85 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 7.78 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 43.59 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. BeOne Medicines Ltd. trades at an EV/FCF ratio of 33.76, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 403.06B versus a market cap of 439.40B, with the gap driven by net debt and cash on the balance sheet.
| EV / Sales | 7.78 |
| EV / EBITDA | 37.85 |
| EV / EBIT | 43.59 |
| EV / FCF | 33.76 |
As of September 30, 2026, BeOne Medicines Ltd. maintains a current ratio of 3.55, meaning it holds 3.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 19.74, indicating elevated leverage, while an interest coverage ratio of 11.80 demonstrates strong ability to service its debt obligations.
| Current Ratio | 3.55 |
| Quick Ratio | 3.10 |
| Debt / Equity | 19.74 |
| Debt / EBITDA | 0.85 |
| Interest Coverage | 11.80 |
Over the twelve months ended September 30, 2026, BeOne Medicines Ltd. posted a return on equity (ROE) of 18.40, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 15.47 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 10.46, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 16.65, useful for judging operating efficiency across full business cycles. The company generates approximately 4.32M in revenue per employee across its workforce of 12,000.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.05 indicates how many times BeOne Medicines Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.
| Return on Equity (ROE) | 18.40 |
| Return on Assets (ROA) | 10.46 |
| Return on Invested Capital (ROIC) | 15.47 |
| Return on Capital Employed (ROCE) | 16.65 |
| Revenue Per Employee | 4.32M |
| Employee Count | 12,000.00 |
| Inventory Turnover | 1.05 |
Over the twelve months ended September 30, 2026, BeOne Medicines Ltd. recorded 1.69B in income tax expense. That works out to an effective tax rate of 19.07, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 8.88B, leaving 7.18B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.
| Income Tax | 1.69B |
| Effective Tax Rate | 19.07 |
As of the close on November 17, 2026, BeOne Medicines Ltd.'s stock has gained approximately 14.75% over the past 52 weeks. The 50-day moving average sits at 222.87, while the 200-day moving average is 197.76.
| 52-Week Price Change | 14.75% |
| 50-Day Moving Average | 222.87 |
| 200-Day Moving Average | 197.76 |
Over the twelve months ended September 30, 2026, BeOne Medicines Ltd. generated 51.83B in revenue and converted that into 7.18B in net income, yielding earnings per share of 3.61. EBITDA reached 10.65B, while operating income came in at 9.25B.
| Revenue | 51.83B |
| Gross Profit | 46.33B |
| Operating Income | 9.25B |
| Pretax Income | 8.88B |
| Net Income | 7.18B |
| EBITDA | 10.65B |
| EBIT | 9.25B |
| Earnings Per Share (EPS) | 3.61 |
As of September 30, 2026, BeOne Medicines Ltd. holds 45.35B in cash and equivalents against 9.01B in total debt, resulting in a net debt position of -36.93B. Total book value stands at 45.66B, with working capital of 44.70B providing operational flexibility.
| Cash & Cash Equivalents | 45.35B |
| Total Debt | 9.01B |
| Net Debt | -36.93B |
| Equity (Book Value) | 45.66B |
| Book Value Per Share | 23.42 |
| Working Capital | 44.70B |
BeOne Medicines Ltd. produced 12.48B in operating cash flow over the twelve months ended September 30, 2026. After subtracting -1.27B in capital expenditures, free cash flow totaled 11.21B - equivalent to 5.85 per share.
| Operating Cash Flow | 12.48B |
| Capital Expenditures | -1.27B |
| Free Cash Flow | 11.21B |
| FCF Per Share | 5.85 |
Over the twelve months ended September 30, 2026, BeOne Medicines Ltd. posted a gross margin of 89.39, reflecting its pricing power and cost economics. The operating margin of 17.84 and net profit margin of 13.86 provide insight into operational efficiency.
| Gross Margin | 89.39 |
| Operating Margin | 17.84 |
| Pretax Margin | 17.12 |
| Profit Margin | 13.86 |
| EBITDA Margin | 20.54 |
These figures cover the twelve months ended September 30, 2026. Free cash flow yield stands at 2.50, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield is negative at -0.47, meaning BeOne Medicines Ltd. raised more capital through share issuance and new debt than it returned via dividends and buybacks.
| Shareholder Yield | -0.47 |
| FCF Yield | 2.50 |
As of September 30, 2026, BeOne Medicines Ltd. has an Altman Z-Score of 8.98, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 8.98 |
Already premium?